← All trials
NCT04209192
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2020
- Primary completion
- Dec 31, 2022
- Completion date
- Feb 28, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 75
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranLead sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranOverall official - principal investigator
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranReponsible party - principal investigator
- Laboratorios Senosiain, S.A. de C.V.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.